NOVEL VALIDATED TARGET definition

NOVEL VALIDATED TARGET means a specific molecule in an intracellular signaling pathway which, when bound by a specific peptide, changes in a predetermined way the phenotype of a target cell with a degree of specificity and in a manner meeting the predetermined validation criteria set by the CMC for Joint Projects and by Novartis for At-Novartis Projects.
View Source
NOVEL VALIDATED TARGET means a Validated Target (other than a Genetics Validated Target) that, at the time of discovery or subsequently during its validation, is: (a) determined to encode a novel Protein based on (i) greater than fifty percent (50%) of the nucleic acid sequence of the full length coding sequence not being present in the Public Domain or (ii) assignment of the Protein to a class of Proteins when such classification was previously unknown; or (b) nove▇▇▇ ▇▇▇otated wherein such novel annotation relates to the role of such Validated Target in (i) respiratory disease or (ii)
View Source

Related to NOVEL VALIDATED TARGET

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Product Candidate means, [***].

  • Soft Target means a target that will suffer minimum damage and cause minimum damage to the subject vehicle in the event of a collision.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.